npj Breast Cancer (Sep 2022)

A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer

  • Natalia Mitin,
  • Kirsten A. Nyrop,
  • Susan L. Strum,
  • Anne Knecht,
  • Lisa A. Carey,
  • Katherine E. Reeder-Hayes,
  • E. Claire Dees,
  • Trevor A. Jolly,
  • Gretchen G. Kimmick,
  • Meghan S. Karuturi,
  • Raquel E. Reinbolt,
  • JoEllen C. Speca,
  • Erin A. O’Hare,
  • Hyman B. Muss

DOI
https://doi.org/10.1038/s41523-022-00473-3
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Identifying patients at higher risk of chemotherapy-induced peripheral neuropathy (CIPN) is a major unmet need given its high incidence, persistence, and detrimental effect on quality of life. We determined if the expression of p16, a biomarker of aging and cellular senescence, predicts CIPN in a prospective, multi-center study of 152 participants enrolled between 2014 and 2018. Any women with newly diagnosed Stage I–III breast cancer scheduled to receive taxane-containing chemotherapy was eligible. The primary outcome was development of grade 2 or higher CIPN during chemotherapy graded by the clinician before each chemotherapy cycle (NCI-CTCAE v5 criteria). We measured p16 expression in peripheral blood T cells by qPCR before and at the end of chemotherapy. A multivariate model identified risk factors for CIPN and included taxane regimen type, p16Age Gap, a measure of discordance between chronological age and p16 expression, and p16 expression before chemotherapy. Participants with higher p16Age Gap—higher chronological age but lower p16 expression prior to chemotherapy - were at the highest risk. In addition, higher levels of p16 before treatment, regardless of patient age, conferred an increased risk of CIPN. Incidence of CIPN positively correlated with chemotherapy-induced increase in p16 expression, with the largest increase seen in participants with the lowest p16 expression before treatment. We have shown that p16 expression levels before treatment can identify patients at high risk for taxane-induced CIPN. If confirmed, p16 might help guide chemotherapy selection in early breast cancer.